{"id":212500,"date":"2026-03-09T15:20:51","date_gmt":"2026-03-09T14:20:51","guid":{"rendered":"https:\/\/efecomunica.efe.com\/?p=212500"},"modified":"2026-03-09T16:47:00","modified_gmt":"2026-03-09T15:47:00","slug":"menarini-nears-e4-9-billion-in-2025-and-focuses-on-talent-and-ai-as-giant-players-enter-pharma","status":"publish","type":"post","link":"https:\/\/efecomunica.efe.com\/en\/menarini-nears-e4-9-billion-in-2025-and-focuses-on-talent-and-ai-as-giant-players-enter-pharma\/","title":{"rendered":"Menarini nears \u20ac4.9 billion in 2025 and focuses on talent and AI as \u2018giant\u2019 players enter pharma"},"content":{"rendered":"

Statement issued by the company (Announcement)<\/p>\n

2025 was a \u201cpositive year\u201d for Menarini<\/strong>, which is celebrating its 140th anniversary this year, despite considerable global \u201cturbulence\u201d. Lucia Aleotti, shareholder and member of the Menarini Board, said so with a smile as she opened the company\u2019s customary annual meeting at the Florence Chamber of Commerce, starting with the figures. The pharmaceutical group, which operates in 140 countries worldwide, reported revenue \u201capproaching \u20ac4.9 billion<\/strong>\u201d \u2014 \u20ac4.887 billion to be precise \u2014 marking a 6.2% increase compared with 2024, with \u201cEBITDA estimated between \u20ac440 million and \u20ac470 million\u201d.<\/p>\n

\n

The strength of women<\/h3>\n

\u201cI would like to open this meeting by highlighting a figure linked to merit. In 2025, for the first time, women outnumbered men: 50.7% of our 17,800 employees are women. These are women who joined purely on merit, because they excel at their jobs. Just as my father used to tell us: \u2018Surround yourselves with people who bring you light\u2019. Because we need exceptional people to help us face this highly demanding competition.\u201d<\/p>\n

The geography of a global company with 905 million units sold worldwide<\/h3>\n

From a geographical perspective, \u201cwe faced some difficulties in Ukraine due to the war, and in Turkey because of currency devaluation and inflation, but we recorded solid growth in Europe, the Middle East and Central America. The United States is now our second-largest market, while China \u2014 which last year fell short of expectations \u2014 delivered a very positive and encouraging trend in 2025, which bodes well for the current year as well.\u201d This growth was driven by demand for a broad range of healthcare products: \u201cWe are talking about around 905 million units sold across 140 countries,\u201d Aleotti said.<\/p>\n

Exchange rate impact and oncology performance<\/h3>\n

The entrepreneur also expressed regret over \u201cthe euro\u2013dollar exchange rate, which cost us almost \u20ac60 million by the end of the year\u201d, but highlighted the strong performance across several therapeutic areas, from cardiovascular disease to diabetes. Oncology, in particular, delivered notable results. \u201cOncology has given us great satisfaction: in 2025 our revenue in the oncology area grew by \u20ac101 million, reaching a total of \u20ac630 million. It is a highly dynamic field and we are competing head-to-head \u2014 sometimes even slightly ahead \u2014 with some of the world\u2019s largest companies.\u201d<\/p>\n

Commitment to research and development from a \u2018prudent\u2019 company<\/h3>\n

Focusing on innovation requires investment. In 2025, Menarini \u201cinvested \u20ac540 million in research and development. These figures reflect our determination to continue along the path of innovation by reinvesting all our profits,\u201d Aleotti told the press. This strategy is made possible by the fact that Menarini is \u201ca private, family-owned company. And also a prudent one, aiming to grow through self-financing without depending on others in its strategic decisions.\u201d<\/p>\n

Notable investments included \u20ac120 million in technology, as well as spending on cybersecurity. \u201cHowever, investment in research and development must ultimately lead to the commercialisation of new medicines and generate economic returns. If the European Commission intends to shorten the duration of patent intellectual property protection, it risks discouraging pharmaceutical companies from investing in research,\u201d Aleotti said.<\/p>\n

The era of the \u2018giants\u2019 and priorities for European companies<\/h3>\n

Something is changing in the pharmaceutical sector. \u201cLarger players \u2014 real giants \u2014 have entered the field: governments. Both the Chinese and US governments are acting to defend their own companies. In this context, European businesses need support and must be backed by policies that help them remain competitive and capable of meeting a crucial global challenge.\u201d This challenge, Aleotti stressed, concerns not only revenues but also \u201cthe independence of our economies\u201d.<\/p>\n

The so-called \u2018pee tax\u2019<\/h3>\n

\u201cWhat is Europe doing instead?\u201d she asked. \u201cThe wastewater directive \u2014 effectively a \u2018pee tax\u2019. Pharmaceutical companies are being asked to purify all of Europe\u2019s rivers because traces of medicines taken by patients end up in urine,\u201d which then flows into water systems. \u201cIt is an anti-industrial policy,\u201d Aleotti argued. \u201cIt has been estimated that this tax will amount to \u20ac12 billion per year paid by companies. That means ten new medicines that will not be developed. China and the United States subsidise their companies, while Europe introduces a \u2018pee tax\u2019.\u201d<\/p>\n

The impact of wars on pharma<\/h3>\n

War is another issue affecting the sector. \u201cInternational tensions are driving up costs, yet pharmaceutical prices in Europe remain frozen: there is zero recovery through sales prices,\u201d Aleotti noted, adding that the Russia\u2013Ukraine conflict has increased drug production costs by around 30%. The new conflict in the Middle East \u2014 a key trade route for goods, including active pharmaceutical ingredients \u2014 is also a source of concern.<\/p>\n

The \u2018jewels\u2019 in Menarini\u2019s pipeline<\/h3>\n

Thanks to its research efforts, the group\u2019s pipeline includes several promising developments. \u201cStarting with the cardiovascular area, we have a next-generation lipid-lowering treatment. If approved for human use, it could become a pill with enormous potential, particularly for patients with difficult-to-treat or therapy-resistant hypercholesterolaemia,\u201d Elcin Barker Ergun, Chief Executive Officer of the Menarini Group, told LaPresse on the sidelines of the 2025 results presentation.<\/p>\n

\u201cAnother project involves an early clinical study for Elacestrant in the treatment of breast cancer, which is also extremely important. It is difficult to imagine a world completely free of cancer, but by combining early screening \u2014 particularly for breast and colorectal cancer \u2014 with pharmaceutical treatments, we can now achieve cures for many patients if the disease is detected in its early stages.\u201d<\/p>\n

AI and a renaissance in healthcare<\/h3>\n

Artificial intelligence is also playing an increasingly important role. According to Ergun, AI is significantly accelerating the discovery of new medicines and does not raise major safety concerns during the research phase, since in most cases it involves small molecules based on robust chemical platforms. \u201cAI accelerates the screening and identification of molecules, but ultimately the process remains the traditional one of chemical synthesis that has always been used to produce medicines,\u201d she said.<\/p>\n

\u201cTraditionally, discovering a new drug requires between five and ten years of work. With AI, this timeframe could be reduced to two or three years. This means we will see more medicines arriving much faster \u2014 which is why I speak of a renaissance in healthcare.\u201d Through its partnership with Insilico Medicine, Menarini \u201cis at the forefront of this approach, which is transforming not only drug discovery but also other stages of development, from identifying patients for clinical trials to regulatory processes,\u201d Ergun concluded.<\/p>\n

For more information:<\/em>\r\nPress Office LaPresse <\/em><\/strong>- <\/em>ufficio.stampa@lapresse.it<\/em><\/a><\/pre>\n

\nAGENCIA EFE S.A.U.,S.M.E. shall not be liable for any information contained in this message and assumes no responsibility towards third parties in relation to its contents, being expressly exempt from any liability that the author may have in relation to the information in question. Agencia EFE reserves the right to distribute the press release on the news wire, or to publish it on EFE Comunica.<\/em>
\n<\/em><\/p>\n<\/div>\n
<\/div>\n","protected":false},"excerpt":{"rendered":"
Statement issued by the company (Announcement) 2025 was a \u201cpositive year\u201d for Menarini, which is celebrating its 140th anniversary this year, despite considerable global \u201cturbulence\u201d. Lucia Aleotti, shareholder and member […]<\/p>\n","protected":false},"author":198164071,"featured_media":48434,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"jetpack_post_was_ever_published":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[125518],"tags":[],"class_list":["post-212500","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-globenewswire-en"],"acf":[],"yoast_head":"\nMenarini nears \u20ac4.9 billion in 2025 and focuses on talent and AI<\/title>\n<meta name=\"description\" content=\"2025 was a \u201cpositive year\u201d for Menarini, which is celebrating its 140th anniversary this year, despite considerable global \u201cturbulence\u201d.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/efecomunica.efe.com\/en\/menarini-nears-e4-9-billion-in-2025-and-focuses-on-talent-and-ai-as-giant-players-enter-pharma\/\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Menarini nears \u20ac4.9 billion in 2025 and focuses on talent and AI","description":"2025 was a \u201cpositive year\u201d for Menarini, which is celebrating its 140th anniversary this year, despite considerable global \u201cturbulence\u201d.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/efecomunica.efe.com\/en\/menarini-nears-e4-9-billion-in-2025-and-focuses-on-talent-and-ai-as-giant-players-enter-pharma\/","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/efecomunica.efe.com\/en\/menarini-nears-e4-9-billion-in-2025-and-focuses-on-talent-and-ai-as-giant-players-enter-pharma\/#article","isPartOf":{"@id":"https:\/\/efecomunica.efe.com\/en\/menarini-nears-e4-9-billion-in-2025-and-focuses-on-talent-and-ai-as-giant-players-enter-pharma\/"},"author":{"name":"EFE","@id":"https:\/\/efecomunica.efe.com\/#\/schema\/person\/38c335f1ce4cd42430576ef5499343b8"},"headline":"Menarini nears \u20ac4.9 billion in 2025 and focuses on talent and AI as \u2018giant\u2019 players enter pharma","datePublished":"2026-03-09T14:20:51+00:00","dateModified":"2026-03-09T15:47:00+00:00","mainEntityOfPage":{"@id":"https:\/\/efecomunica.efe.com\/en\/menarini-nears-e4-9-billion-in-2025-and-focuses-on-talent-and-ai-as-giant-players-enter-pharma\/"},"wordCount":1114,"publisher":{"@id":"https:\/\/efecomunica.efe.com\/#organization"},"image":{"@id":"https:\/\/efecomunica.efe.com\/en\/menarini-nears-e4-9-billion-in-2025-and-focuses-on-talent-and-ai-as-giant-players-enter-pharma\/#primaryimage"},"thumbnailUrl":"https:\/\/efecomunica.efe.com\/wp-content\/uploads\/2022\/10\/Notified-GlobeNewswire-Color-Large-1.jpg","articleSection":["Globenewswire"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/efecomunica.efe.com\/en\/menarini-nears-e4-9-billion-in-2025-and-focuses-on-talent-and-ai-as-giant-players-enter-pharma\/","url":"https:\/\/efecomunica.efe.com\/en\/menarini-nears-e4-9-billion-in-2025-and-focuses-on-talent-and-ai-as-giant-players-enter-pharma\/","name":"Menarini nears \u20ac4.9 billion in 2025 and focuses on talent and AI","isPartOf":{"@id":"https:\/\/efecomunica.efe.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/efecomunica.efe.com\/en\/menarini-nears-e4-9-billion-in-2025-and-focuses-on-talent-and-ai-as-giant-players-enter-pharma\/#primaryimage"},"image":{"@id":"https:\/\/efecomunica.efe.com\/en\/menarini-nears-e4-9-billion-in-2025-and-focuses-on-talent-and-ai-as-giant-players-enter-pharma\/#primaryimage"},"thumbnailUrl":"https:\/\/efecomunica.efe.com\/wp-content\/uploads\/2022\/10\/Notified-GlobeNewswire-Color-Large-1.jpg","datePublished":"2026-03-09T14:20:51+00:00","dateModified":"2026-03-09T15:47:00+00:00","description":"2025 was a \u201cpositive year\u201d for Menarini, which is celebrating its 140th anniversary this year, despite considerable global \u201cturbulence\u201d.","breadcrumb":{"@id":"https:\/\/efecomunica.efe.com\/en\/menarini-nears-e4-9-billion-in-2025-and-focuses-on-talent-and-ai-as-giant-players-enter-pharma\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/efecomunica.efe.com\/en\/menarini-nears-e4-9-billion-in-2025-and-focuses-on-talent-and-ai-as-giant-players-enter-pharma\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/efecomunica.efe.com\/en\/menarini-nears-e4-9-billion-in-2025-and-focuses-on-talent-and-ai-as-giant-players-enter-pharma\/#primaryimage","url":"https:\/\/efecomunica.efe.com\/wp-content\/uploads\/2022\/10\/Notified-GlobeNewswire-Color-Large-1.jpg","contentUrl":"https:\/\/efecomunica.efe.com\/wp-content\/uploads\/2022\/10\/Notified-GlobeNewswire-Color-Large-1.jpg","width":1200,"height":650,"caption":"El \u00edndice Moneyball de Squawka clasifica a los clubes de la Premier League tomando en cuenta las \u00faltimas cinco temporadas (incluida la 2025\/26)."},{"@type":"BreadcrumbList","@id":"https:\/\/efecomunica.efe.com\/en\/menarini-nears-e4-9-billion-in-2025-and-focuses-on-talent-and-ai-as-giant-players-enter-pharma\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/efecomunica.efe.com\/"},{"@type":"ListItem","position":2,"name":"Menarini nears \u20ac4.9 billion in 2025 and focuses on talent and AI as \u2018giant\u2019 players enter pharma"}]},{"@type":"WebSite","@id":"https:\/\/efecomunica.efe.com\/#website","url":"https:\/\/efecomunica.efe.com\/","name":"EFE Comunica","description":"Contenidos para empresas","publisher":{"@id":"https:\/\/efecomunica.efe.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/efecomunica.efe.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/efecomunica.efe.com\/#organization","name":"EFE Comunica","url":"https:\/\/efecomunica.efe.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/efecomunica.efe.com\/#\/schema\/logo\/image\/","url":"https:\/\/efecomunica.efe.com\/wp-content\/uploads\/2020\/12\/Logo-EFE-Comunica_png.png","contentUrl":"https:\/\/efecomunica.efe.com\/wp-content\/uploads\/2020\/12\/Logo-EFE-Comunica_png.png","width":1080,"height":486,"caption":"EFE Comunica"},"image":{"@id":"https:\/\/efecomunica.efe.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/EFEComunicaAgenciaEFE","https:\/\/x.com\/EFEcomunica","https:\/\/www.linkedin.com\/showcase\/efecomunica"]},{"@type":"Person","@id":"https:\/\/efecomunica.efe.com\/#\/schema\/person\/38c335f1ce4cd42430576ef5499343b8","name":"EFE","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/e5fcf26bedbd04dc20896c519164a13fe69c6913f5830d7db51543fa04eb30b4?s=96&d=identicon&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e5fcf26bedbd04dc20896c519164a13fe69c6913f5830d7db51543fa04eb30b4?s=96&d=identicon&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e5fcf26bedbd04dc20896c519164a13fe69c6913f5830d7db51543fa04eb30b4?s=96&d=identicon&r=g","caption":"EFE"},"sameAs":["http:\/\/efe.com"],"url":"https:\/\/efecomunica.efe.com\/en\/author\/efedesarrollo\/"}]}},"jetpack_featured_media_url":"https:\/\/efecomunica.efe.com\/wp-content\/uploads\/2022\/10\/Notified-GlobeNewswire-Color-Large-1.jpg","jetpack_likes_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/pcEg1r-Thq","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/efecomunica.efe.com\/en\/wp-json\/wp\/v2\/posts\/212500","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/efecomunica.efe.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/efecomunica.efe.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/efecomunica.efe.com\/en\/wp-json\/wp\/v2\/users\/198164071"}],"replies":[{"embeddable":true,"href":"https:\/\/efecomunica.efe.com\/en\/wp-json\/wp\/v2\/comments?post=212500"}],"version-history":[{"count":4,"href":"https:\/\/efecomunica.efe.com\/en\/wp-json\/wp\/v2\/posts\/212500\/revisions"}],"predecessor-version":[{"id":212518,"href":"https:\/\/efecomunica.efe.com\/en\/wp-json\/wp\/v2\/posts\/212500\/revisions\/212518"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/efecomunica.efe.com\/en\/wp-json\/wp\/v2\/media\/48434"}],"wp:attachment":[{"href":"https:\/\/efecomunica.efe.com\/en\/wp-json\/wp\/v2\/media?parent=212500"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/efecomunica.efe.com\/en\/wp-json\/wp\/v2\/categories?post=212500"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/efecomunica.efe.com\/en\/wp-json\/wp\/v2\/tags?post=212500"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}